Trokendi vs Qudexy

Quote












Anonymous said:
I already am there you idiot. Our launch was quick and the uptake is going great. Can't say the same for you.
Click to expand...

First, keep drinking that koolaid that your company is feeding you. Second, you better pray that things fall apart at USL because if they don't and QudexyXR is actually launched, which is very likely, your product is dead in the water. Third, why don't you go to your company threads and join them and defend the company. It needs you as it seems there some really unhappy people there. Your company's progress remains to be seen after the earnings coming up on May 13th. Right now, your numbers are not impressive especially considering you are approaching one year since launch.
 






Anonymous said:
You are correct! USL headed to bankruptcy.
Click to expand...

Obviously a Supernus person who doesn't know shit about our company. Learning time for the feeble minded. USL doesn't have debt. It has a base business of generics that brings in north of $500M/year. This base business fuels the future and pays the bills without needing external financing, unlike Supernus which is drowning in debt. Will USL be successful in the launch of its CNS division and product? We will see. Most probably, but who knows. One thing is for sure though, when QudexyXR launches, TrokendiXR is finished. Game over for that product of yours.
 






What makes you think Trokendi XR is "done" or "finished"? Everything I have seen suggests that the 2 are pretty much identical drugs. I think we will have an uphill battle given that they have a 6 month head start already
 






Anonymous said:
What makes you think Trokendi XR is "done" or "finished"? Everything I have seen suggests that the 2 are pretty much identical drugs. I think we will have an uphill battle given that they have a 6 month head start already
Click to expand...

C'mon, seriously?!!!!! You answered your own question and you don't even know it. Yes, QudexyXR and TrokendiXR are virtually identical but we have a sprinkle option and we have phase 3 clinical data. More importantly, we have a unique marketing strategy. If our strategy rolls out the way we plan, and we execute with precision, within 6 months TrokendiXR is "done". Just think about it. That said, if our marketing strategy doesn't roll out the way we want and plan it to, then yes, it may very well be an uphill battle. I think we are going to do well.
 






Anonymous said:
Obviously a Supernus person who doesn't know shit about our company. Learning time for the feeble minded. USL doesn't have debt. It has a base business of generics that brings in north of $500M/year. This base business fuels the future and pays the bills without needing external financing, unlike Supernus which is drowning in debt. Will USL be successful in the launch of its CNS division and product? We will see. Most probably, but who knows. One thing is for sure though, when QudexyXR launches, TrokendiXR is finished. Game over for that product of yours.
Click to expand...

No debt!! HAHAHAHA! 540 million borrowed from J.P. Morgan, Wells Fargo, etc. to buy Proximigen!
 


















Anonymous said:
C'mon, seriously?!!!!! You answered your own question and you don't even know it. Yes, QudexyXR and TrokendiXR are virtually identical but we have a sprinkle option and we have phase 3 clinical data. More importantly, we have a unique marketing strategy. If our strategy rolls out the way we plan, and we execute with precision, within 6 months TrokendiXR is "done". Just think about it. That said, if our marketing strategy doesn't roll out the way we want and plan it to, then yes, it may very well be an uphill battle. I think we are going to do well.
Click to expand...


hahaha, you think a sprinkle indication and a stage 3 study will make doctors eyes light up?? Doctors will do whatever they want and will sprinkle it even if its not indicated because topiramate is topiramate. Have fun telling your stage 3 study and how efficacious it is for epilepsy patients when they only take 1% of the topiramate population. I hope your marketing strategy involves a hot 22 year old chick because what I have seen is when it comes down to putting pen to paper, doctors are going to prescribe to who he/she has a better relationship with and what they have tried and trust. Not saying its not possible, but relationships and having almost a 1 year head start sounds good to me!
 






Anonymous said:
hahaha, you think a sprinkle indication and a stage 3 study will make doctors eyes light up?? Doctors will do whatever they want and will sprinkle it even if its not indicated because topiramate is topiramate. Have fun telling your stage 3 study and how efficacious it is for epilepsy patients when they only take 1% of the topiramate population. I hope your marketing strategy involves a hot 22 year old chick because what I have seen is when it comes down to putting pen to paper, doctors are going to prescribe to who he/she has a better relationship with and what they have tried and trust. Not saying its not possible, but relationships and having almost a 1 year head start sounds good to me!
Click to expand...

Lol, I know they are really reaching.
 






Anonymous said:
hahaha, you think a sprinkle indication and a stage 3 study will make doctors eyes light up?? Doctors will do whatever they want and will sprinkle it even if its not indicated because topiramate is topiramate. Have fun telling your stage 3 study and how efficacious it is for epilepsy patients when they only take 1% of the topiramate population. I hope your marketing strategy involves a hot 22 year old chick because what I have seen is when it comes down to putting pen to paper, doctors are going to prescribe to who he/she has a better relationship with and what they have tried and trust. Not saying its not possible, but relationships and having almost a 1 year head start sounds good to me!
Click to expand...

I agree that relationships play a big role and that an almost one year head start weighs a lot, but what matters most, above all, is managed care coverage and access to the product. Whoever has better managed care coverage and makes it easy for patients to get the product and easy for the docs to prescribe it, will win. Let's see how it all plays out.
 






I felt bad for all the reps that were hired to sell this product in the beginning because there is not enough room in the market for 2 XR topiramates no debate there. Then you get approval and don't launch the product and have your reps sitting at home collecting salary I guess that's just pitiful.
 












Anonymous said:
Generic companies don't need reps. USL is going to try to undercut on price. The only thing they know.
Click to expand...

The comical thing is that is exactly what USL will do. The irony is this was their attempt to rebrand USL as a non generic company. What a joke USL has become if they don't even know their identity. Put that on the drawing board upper mgmt.
 












Ok, I know I'm late to the party here, and am a patient, but I need info and can't find it anywhere. I'm on Trokendi for migraines, after having taken Topamax for several years but having to quit b/c side effects were horrific. Trokendi's are pretty bad, too, despite what my neuro says. I've read that Qudexy is more tolerable, but is it even available? My neuro says he hasn't heard of it, but I'm not sure he's being completely honest.
 






  • No one   Dec 17, 2015 at 10:46: PM
anonymous said:
Ok, I know I'm late to the party here, and am a patient, but I need info and can't find it anywhere. I'm on Trokendi for migraines, after having taken Topamax for several years but having to quit b/c side effects were horrific. Trokendi's are pretty bad, too, despite what my neuro says. I've read that Qudexy is more tolerable, but is it even available? My neuro says he hasn't heard of it, but I'm not sure he's being completely honest.
Click to expand...
If you can't tolerate Trokendi, you definitely won't tolerate Qudexy.
 












Anonymous said:
C'mon, seriously?!!!!! You answered your own question and you don't even know it. Yes, QudexyXR and TrokendiXR are virtually identical but we have a sprinkle option and we have phase 3 clinical data. More importantly, we have a unique marketing strategy. If our strategy rolls out the way we plan, and we execute with precision, within 6 months TrokendiXR is "done". Just think about it. That said, if our marketing strategy doesn't roll out the way we want and plan it to, then yes, it may very well be an uphill battle. I think we are going to do well.
Click to expand...
You still optimistic? Looks like your so called plan didn't workout to well. Looks like your plan was to copy what your competitor was doing, but then again what else could you expect from a generic company. You should just crawl in a hole and burry yourself. You are embarrassing yourselves in the market.
 






Top Bottom
Back
Quote